Kura Oncology (NASDAQ:KURA) Price Target Lowered to $10.00 at Scotiabank

Kura Oncology (NASDAQ:KURA) had its price objective dropped by stock analysts at Scotiabank from $18.00 to $10.00 in a note issued to investors on Wednesday,Benzinga reports. The firm presently has a “sector perform” rating on the stock. Scotiabank’s price objective would suggest a potential upside of 22.40% from the company’s previous close.

Several other research analysts also recently weighed in on KURA. Stifel Nicolaus downgraded Kura Oncology from a “buy” rating to a “hold” rating and cut their price target for the stock from $26.00 to $19.00 in a research note on Monday, October 14th. HC Wainwright increased their target price on shares of Kura Oncology from $32.00 to $37.00 and gave the stock a “buy” rating in a research report on Thursday, November 21st. Lifesci Capital upgraded shares of Kura Oncology to a “strong-buy” rating in a research note on Tuesday, October 22nd. Wedbush restated an “outperform” rating and set a $37.00 price target on shares of Kura Oncology in a research note on Monday, November 4th. Finally, UBS Group assumed coverage on shares of Kura Oncology in a report on Thursday, October 24th. They issued a “buy” rating and a $27.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $27.38.

Kura Oncology Price Performance

Kura Oncology stock opened at $8.17 on Wednesday. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02. The business’s 50 day simple moving average is $12.11 and its 200 day simple moving average is $17.08. Kura Oncology has a 12 month low of $8.13 and a 12 month high of $24.17. The company has a market cap of $635.33 million, a price-to-earnings ratio of -3.46 and a beta of 0.81.

Institutional Trading of Kura Oncology

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. JPMorgan Chase & Co. grew its position in shares of Kura Oncology by 0.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 409,241 shares of the company’s stock valued at $7,997,000 after purchasing an additional 3,092 shares in the last quarter. Franklin Resources Inc. boosted its stake in Kura Oncology by 1.5% during the third quarter. Franklin Resources Inc. now owns 1,588,401 shares of the company’s stock valued at $28,687,000 after buying an additional 23,113 shares during the period. Geode Capital Management LLC grew its position in Kura Oncology by 2.4% during the third quarter. Geode Capital Management LLC now owns 1,780,509 shares of the company’s stock worth $34,798,000 after buying an additional 41,535 shares in the last quarter. Barclays PLC increased its stake in Kura Oncology by 104.5% in the 3rd quarter. Barclays PLC now owns 165,484 shares of the company’s stock worth $3,234,000 after acquiring an additional 84,563 shares during the last quarter. Finally, Jane Street Group LLC increased its stake in Kura Oncology by 36.7% in the 3rd quarter. Jane Street Group LLC now owns 126,085 shares of the company’s stock worth $2,464,000 after acquiring an additional 33,848 shares during the last quarter.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.